Retinal hemorrhages following fingolimod treatment for multiple sclerosis; a case report

BMC Ophthalmology

Case Report

Kyoko Saida¹  Naoko Ueda² 

[1] Department of Neurology, Kyoto Hakuaikai Hospital, 1 Keshiyama, Kamigamo, Kita-ku, 603-8041, Kyoto, Japan;Department of Ophthalmology, Kyoto Hakuaikai Hospital, 1 Keshiyama, Kamigamo, Kita-ku, 603-8041, Kyoto, Japan;

关键词: Retinal hemorrhages;    Fingolimod;    Relapsing-remitting multiple sclerosis;    Side effect;    Macular edema;   

DOI  :  10.1186/s12886-015-0125-9

 received in 2015-06-22, accepted in 2015-10-09,  发布年份 2015

来源: Springer

【 摘 要 】

BackgroundFingolimod is the first oral agent used for treatment of relapsing-remitting multiple sclerosis. Macular edema, but not retinal hemorrhage, is a well-known adverse effect of fingolimod treatment. To the best of our knowledge, this is the first case report of extensive retinal hemorrhages following fingolimod treatment.Case presentationA 31-year-old male with relapsing-remitting multiple sclerosis developed macular edema and retinal hemorrhages in his left eye, 1 month after starting fingolimod treatment; treatment was then discontinued. The hemorrhages were flame-shaped, and were extensive along retinal arteries and veins. The hemorrhages started to decrease at 4 weeks and disappeared completely at 24 weeks after cessation of fingolimod treatment.ConclusionsOccurrence of retinal hemorrhage warrants careful follow-up for multiple sclerosis patients treated with fingolimod.

【 授权许可】

CC BY   
© Ueda and Saida. 2015